Patient Files Lawsuit Over Glucose Sensor Accuracy
A new lawsuit alleges a malfunctioning sensor led to an unnecessary emergency visit for an individual with diabetes.
Updated on Oct. 28, 2026 in Diabetes
Live Poll
Should medical device companies be held strictly liable for inaccurate data causing patient emergency room visits?
A plaintiff has filed a lawsuit against Abbott Laboratories, alleging a defective FreeStyle Libre 3 Plus sensor provided inaccurate, dangerously low blood sugar readings. The case follows several recent Class I recalls issued for the company's continuous glucose monitoring devices.
Why it matters
This litigation highlights ongoing concerns regarding the reliability of continuous glucose monitoring technology. Patients rely on these devices to manage daily insulin dosing and blood sugar levels, making accurate data reporting critical to avoiding emergency medical interventions.
The FDA issued Class I recall classifications in September 2024 and January 2026 for millions of FreeStyle Libre sensors. While these regulatory actions addressed false readings, the specific diagnostic accuracy of the device in this new legal complaint remains under investigation.
The players
Abbott Laboratories
A healthcare company that develops medical devices, including continuous glucose monitoring systems used for diabetes management.
Andrew Vincent
The plaintiff who filed a product liability lawsuit against the manufacturer after an alleged sensor malfunction.
The details
Continuous glucose monitors work by using a sensor filament inserted just under the skin to measure glucose levels in the interstitial fluid. These sensors transmit real-time data to a receiver, which can alert users to fluctuations that may require immediate medical or nutritional attention. The lawsuit claims that the device produced readings so inaccurate they prompted an emergency room visit, highlighting the potential consequences when these systems fail to perform within their specified parameters.
Timeline
July 2024: Abbott announced a recall for FreeStyle Libre 3 sensors.
September 2024: The FDA classified the July 2024 recall as Class I.
November 2025: Abbott initiated a recall of 3 million sensors.
January 2026: The FDA classified the November 2025 recall as Class I.
October 20, 2026: Andrew Vincent filed the product liability lawsuit.
Health Landscape
The lawsuit follows a pattern set by the January 2026 FDA Class I classification of the November 2025 FreeStyle Libre sensor recall. This case underscores the evolving regulatory scrutiny surrounding the accuracy of digital health tools used for chronic disease management.
If you use a continuous glucose monitor and receive a reading that feels inconsistent with your symptoms, it is worth confirming the result with a traditional finger-stick blood glucose meter. Discuss any patterns of unexpected or concerning device alerts with your physician to ensure your treatment plan remains safe.
The takeaway
When medical devices show conflicting data, relying on manual verification methods like finger-stick testing provides an essential safety net. Always keep a standard glucose monitor and testing strips on hand to cross-reference sensor readings during unexpected health events.
Further reading
For more on how to safely manage glucose monitoring, visit Diabetes.
Source note: This article includes information reported by AboutLawsuits.
Live Poll
Should medical device companies be held strictly liable for inaccurate data causing patient emergency room visits?
